Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionCIBC Asset Management Inc
Latest Disclosed Ownership29,472 shares
Latest Disclosed Value $ 9,751,401
CIBC Asset Management Inc reports 1.21% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - CIBC Asset Management Inc filed a 13F-HR form disclosing ownership of 29,472 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $8,420,150 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 29,832 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -1.21% during the quarter. The current value of the position is $7,677,456 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,472 -360 -1.21 9,751 -17.80 0.0238
2026-02-10 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,832 24,334 442.60 11,863 373.16 0.0286
2025-10-31 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,498 40 0.73 2,507 40.92 0.0073
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,458 36 0.66 1,780 21.52 0.0055
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,422 288 5.61 1,464 21.19 0.0049
2025-01-31 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,134 651 14.52 1,208 -1.95 0.0040
2024-11-06 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,483 234 5.51 1,233 19.38 0.0040
2024-08-01 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,249 227 5.64 1,033 71.71 0.0037
2024-05-09 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,022 8 0.20 601 -21.74 0.0021
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,014 -308 -7.13 768 0.39 0.0029
2023-10-30 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,322 128 3.05 765 -3.89 0.0032
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,194 3 0.07 797 -5.13 0.0031
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,191 84 2.05 840 -14.04 0.0033
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,107 -1,199 -22.60 976 -8.10 0.0041
2022-11-03 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,306 14 0.26 1,062 37.56 0.0047
2022-08-09 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,292 -95 -1.76 772 -12.27 0.0031
2022-05-06 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,387 28 0.52 880 -3.19 0.0031
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,359 581 12.16 909 0.78 0.0033
2021-11-09 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,778 427 9.81 902 22.22 0.0036
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,351 11 0.25 738 20.39 0.0030
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,340 161 3.85 613 12.89 0.0026
2021-02-03 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,179 0 0.00 543 -10.69 0.0026
2020-11-05 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,179 103 2.53 608 0.66 0.0031
2020-07-28 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,076 0 0.00 604 36.04 0.0035
2020-04-30 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,076 -699 -14.64 444 -19.27 0.0031
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,775 521 12.25 550 60.82 0.0031
2019-10-30 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,254 -273 -6.03 342 4.27 0.0020
2019-08-05 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,527 0 0.00 328 -22.46 0.0020
2019-05-06 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,527 560 14.12 423 46.37 0.0026
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,967 -15 -0.38 289 -17.19 0.0021
2018-11-02 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,982 -114 -2.78 349 -13.40 0.0022
2018-08-09 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,096 465 12.81 403 -6.71 0.0025
2018-04-30 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,631 541 17.51 432 9.92 0.0028
2018-02-02 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,090 0 0.00 393 8.26 0.0024
2017-11-06 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,090 313 11.27 363 64.25 0.0023
2017-07-27 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,777 2,777 221 0.0015
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,463 -100.00 0 -100.00
2016-10-19 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,463 344 8.35 303 32.31 0.0022
2016-08-02 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,119 46 1.13 229 -10.55 0.0017
2016-05-09 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,073 422 11.56 256 -25.58 0.0019
2016-02-02 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,651 475 14.96 344 34.90 0.0028
2015-11-03 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,176 609 23.72 255 -17.21 0.0020
2015-08-06 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,567 314 13.94 308 31.06 0.0021
2015-05-08 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,253 2,253 235 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.